Home / Inspections / 1218069

FDA Inspection 1218069 — Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC

Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC — FEI 1222181

The FDA completed an inspection of Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC on September 19, 2023 in Andover, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 19, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Andover, MA (United States)

Facility

Other inspections at this facility

  • 1311392 (VAI Wed Apr 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1304580 (NAI Wed Feb 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1223617 (NAI Fri Oct 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1020234 (VAI Fri Apr 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 988784 (VAI Fri Sep 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources